Hims & Hers Health, Inc. (NYSE:HIMS) Shares Purchased by Two Sigma Advisers LP

Two Sigma Advisers LP lifted its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 839.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 524,100 shares of the company's stock after acquiring an additional 468,300 shares during the period. Two Sigma Advisers LP owned approximately 0.24% of Hims & Hers Health worth $12,673,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in HIMS. Crewe Advisors LLC acquired a new stake in Hims & Hers Health during the 4th quarter valued at $28,000. Raleigh Capital Management Inc. grew its holdings in Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 1,100 shares in the last quarter. Blume Capital Management Inc. grew its holdings in Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 600 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after purchasing an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC acquired a new stake in Hims & Hers Health during the 4th quarter valued at $38,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Insider Buying and Selling

In related news, COO Melissa Baird sold 33,333 shares of the business's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $25.78, for a total transaction of $859,324.74. Following the sale, the chief operating officer now owns 805,083 shares of the company's stock, valued at $20,755,039.74. The trade was a 3.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michael Chi sold 17,303 shares of the business's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $48.14, for a total value of $832,966.42. Following the sale, the insider now directly owns 193,601 shares in the company, valued at approximately $9,319,952.14. The trade was a 8.20% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 618,936 shares of company stock valued at $25,182,692 over the last quarter. Corporate insiders own 13.71% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have commented on HIMS shares. Canaccord Genuity Group increased their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Citigroup reiterated a "sell" rating and set a $30.00 price objective (up from $25.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Leerink Partners increased their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research note on Tuesday, February 25th. Truist Financial reduced their price objective on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research note on Thursday, April 10th. Finally, Wall Street Zen upgraded shares of Hims & Hers Health from a "hold" rating to a "buy" rating in a research note on Thursday. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health has a consensus rating of "Hold" and a consensus target price of $37.67.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock traded up $1.37 during trading hours on Friday, reaching $54.89. The company's stock had a trading volume of 23,551,640 shares, compared to its average volume of 19,610,998. The company's 50 day simple moving average is $37.95 and its 200 day simple moving average is $35.08. The stock has a market cap of $12.29 billion, a P/E ratio of 124.75 and a beta of 1.84. Hims & Hers Health, Inc. has a one year low of $13.47 and a one year high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. The company had revenue of $586.01 million for the quarter, compared to analysts' expectations of $535.21 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business's revenue for the quarter was up 110.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.05 earnings per share. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.